Ariad to resume sales of cancer drug Iclusig, shares jump

[riky]

Ariad to resume sales of cancer drug Iclusig, shares jump

A leukemia drug that was suspended amid safety concerns nearly two months ago is being allowed back on the U.S. market, though restricted to a smaller group of patients. Shares of Ariad Pharmaceuticals Inc, which makes the drug, Iclusig, rose as much as 40 percent after news that the U.S. Food and Drug Administration approved the more restricted use of on Friday. Iclusig was approved a year ago to treat chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia in patients who had failed to respond to at least one other therapy. The FDA said it approved a revised label for the drug, limiting its use to patients with a specific genetic mutation and to those who are unable to use alternative treatments such as Novartis AG's Gleevec or Bristol Myers Squibb Co's Sprycel.

Source: You are not allowed to view links. Register or Login